USPTO serial 79403022
WHY WAIT!
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 21, 2026
- Examiner
- FOSDICK, GEOFFREY A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with WHY WAIT!?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Clinically Approved Holdings Pty Ltd
AU
Other trademarks owned by Clinically Approved Holdings Pty Ltd
Clinically Approved Holdings Pty Ltd
AU
Other trademarks owned by Clinically Approved Holdings Pty Ltd
Clinically Approved Holdings Pty Ltd
AU
Other trademarks owned by Clinically Approved Holdings Pty Ltd
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Amy C. Ziegler
Amy C. Ziegler Greer, Burns & Crain Ltd.200 West Madison StreetSuite 2100Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vitamins; mineral supplements; nutritional supplements; multivitamin preparations; pharmaceutical preparations containing vitamins for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations containing omega 3 for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations for metabolic support; pharmaceutical preparations for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical preparations containing vitamins for pregnancy; vitamin supplements; vitamin fortified beverages for medical use; vitamin preparations; medicines for treatment of heart diseases; pharmaceutical products for combating heart diseases; pharmaceutical tablets for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets containing omega 3 for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets for metabolic support; pharmaceutical tablets for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical tablets containing vitamins for pregnancy; anti-inflammatories; vitamin mineral and herbal preparations in tablet and powder form for medical use; dietary nutritional supplements; dietary supplements; dietetic drinks adapted for medical purposes; dietetic food supplements adapted for medical purposes; effervescent vitamin tablets; herbal extracts, other than essential oils, for medical purposes; food supplements, namely, antioxidants, omega 3; dietary food supplements; medicated food supplements; nutritionally fortified beverages adapted for medical purposes; therapeutic agents for weight control and appetite suppression; vitamin tablets; dietary supplements in powder form; medicinal drinks; dietary supplements in capsule form; dietary supplements in liquid capsule form; gummy vitamins; medicines and chemical compounds for the treatment and support of blood circulation; pharmaceutical preparations, medicines and chemical compounds for the treatment of cardiovascular diseases; pharmaceutical preparations, medicines and chemical compounds for the health of blood cells and production of blood lipids, pharmaceutical preparations, medicines and chemical compounds for treatment of cells exposed to oxidants; pharmaceutical preparations, medicines and chemical compounds to treat blood disorders; pharmaceutical preparations, medicines and chemical compounds to treat cardiovascular diseases and for cardiovascular health; chemical preparations for the treatment of cognitive decline; chemical preparations for the treatment of anxiety; chemical preparations for depression; pharmaceutical preparations for the treatment of alzheimers disease; pharmaceutical preparations for the treatment and management of coronavirus disease; pharmaceutical preparations for strengthening human immune responses; pharmaceutical preparations for treatment of influenza variations; pharmaceutical preparations for sleep support; mineral food supplements; analgesics and analgesic preparations; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat blood circulation, artery wellness and strong cardiovascular system, heart disease, healthy red blood cell production and healthy blood lipids, cell energy and to protect cells from oxidative damage and calcium absorption and to maintain healthy blood glucose, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat excessive immune response in relation to coronavirus disease, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to treat for excessive immune response in humans with influenza, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat Alzheimer's disease, age related mental decline, anxiety and depression, brain fog, stress, ADHD, slow memory and cognitive decline; analgesic preparations, medicines and chemical compounds to improve brain function, brain health during pregnancy and early childhood in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat joint pain, joint disease, arthritis, mild joint aches, and to maintain joint mobility and/or flexibility, healthy joint cartilage growth and/or joint health, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support and assist sleep quality, sleep patterns, and the time required to fall asleep, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to increase calmness, support healthy stress response in the human body, reduce stress and anxiety, relieve symptoms of stress, anxiety or nervous tension, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, and medicines and chemical compounds for the relief and treatment of pain, inflammation, discomfort and swelling in connection with or related to any body component including, without limitation, muscular aches and pains, backache, headache, migraine headache, tension headache, sinus pain, toothache, dental pain, period pain, sore throat, tennis elbow, rheumatic pain, aches and pains associated with colds and flu, female period pain, pain and sleep, pain in connection with manual and/or physical labour, and/or pain in connection with the recovery of injury, harm, decline and damage to any body component, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds to support and treat eye vision, age-related eye diseases, eye health, eye conditions including dry eye, aged-related Macular Degeneration and/or cataracts, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of the health and quality of skin, cell growth and renewal, skin damage, skin wrinkle depth, skin hydration, skin appearance, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of heart health, brain health, eye health, muscle health, joint health, colon, prostate and breast cancers, metabolic syndrome, in liquid, tablet, capsule, powder, tea and gummy form | ACTIVE | — |
| 032 | Non-alcoholic beverages, namely, carbonated beverages; concentrates and powders used in the preparation of soft drinks; drinking water | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Clinically Approved Holdings Pty Ltd
- Other trademarks owned by Clinically Approved Holdings Pty Ltd
- Other trademarks owned by Clinically Approved Holdings Pty Ltd
- Other trademarks in Class 005
- Other trademarks in Class 032
- Similar marks named WHY WAIT!
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 21, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 21, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 21, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 26, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 12, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 10, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 3, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 3, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 3, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 3, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 27, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 5, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 5, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 5, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 4, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 4, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 16, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 15, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 15, 2025 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Dec 20, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 30, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 30, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |